A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of DCTY1102 Injection in Patients With Advanced Solid Tumors Positive for KRAS G12D Mutation and HLA-A*11:01 Genotype
Latest Information Update: 17 Jun 2025
At a glance
- Drugs DCTY 1102 (Primary)
- Indications Colorectal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Beijing DCTY Biotech
Most Recent Events
- 17 Jun 2025 New trial record